Simponi

Conditions Treated

Simponi is an injectable medication used to treat adults and some children with the following inflammatory conditions:

• Rheumatoid Arthritis: Used for adults with moderate to severe active rheumatoid arthritis. It is usually taken along with methotrexate.
• Psoriatic Arthritis: Used for adults with active psoriatic arthritis. It may be used alone or with methotrexate.
• Ankylosing Spondylitis: Used for adults with active ankylosing spondylitis, a chronic inflammatory disease of the spine and large joints.
• Ulcerative Colitis: Used for adults and children aged 2 years and older with moderate to severe active ulcerative colitis. It is typically prescribed when other treatments have not been effective or when there is a need to stop or reduce the use of corticosteroid medicines.

The medication works by targeting specific proteins in the body that cause inflammation, helping to reduce swelling, pain, and joint damage over time.

Targeting Inflammation

Simponi belongs to a class of medications known as tumor necrosis factor (TNF) blockers. It is a monoclonal antibody designed to recognize and bind to a specific protein in the body called TNF-alpha.

The Role of TNF-alpha

TNF-alpha is a substance naturally produced by the immune system to help the body fight infections. However, in people with certain autoimmune conditions, the body produces too much of this protein. Excessive levels of TNF-alpha lead to chronic inflammation, which can cause:

• Pain and swelling in the joints.
• Stiffness and decreased mobility.
• Damage to the lining of the large intestine.

How Simponi Intervenes

When Simponi is administered, it seeks out TNF-alpha proteins and attaches to them. By binding to these proteins, Simponi prevents them from interacting with healthy cells. This action effectively blocks the inflammatory signals that would otherwise tell the immune system to attack the body's own tissues. By lowering the activity of TNF-alpha, the medication helps to decrease inflammation, manage symptoms, and potentially slow the progression of joint damage.

Common Side Effects

Many people using Simponi experience mild side effects. These often include:

• Upper respiratory infections, such as the common cold, sinus pain, or sore throat.
• Injection site reactions, including redness, itching, pain, or swelling where the medicine was injected.
• Nausea.
• Dizziness.
• Cold sores or fever blisters.

Serious Side Effects

While less common, some side effects can be severe and require immediate medical attention. Contact a healthcare provider right away if you experience:

• Signs of infection: Fever, chills, persistent cough, muscle aches, or feeling very tired.
• Heart problems: New or worsening shortness of breath, swelling of the ankles or feet, or sudden weight gain.
• Liver issues: Yellowing of the skin or eyes (jaundice), dark urine, or pain on the right side of the stomach.
• Nervous system disorders: Numbness, tingling, vision changes, or weakness in the arms or legs.
• Immune system reactions: A lupus-like syndrome characterized by joint pain or a rash on the cheeks or arms that worsens in the sun.
• Blood disorders: Easy bruising, bleeding, or looking very pale.
• New or worsening psoriasis: Red, scaly patches or bumps filled with pus on the skin.

Severe allergic reactions are rare but possible. Seek emergency help for hives, swelling of the face or throat, or difficulty breathing.

Serious Infections

Simponi affects the immune system and can increase the risk of serious infections, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections. These infections may lead to hospitalization or death. Healthcare providers typically test for TB before starting treatment and monitor for signs of infection throughout therapy. Treatment should not be initiated in individuals with an active infection.

Malignancies

Lymphoma and other cancers, some fatal, have been reported in children and adolescent patients using TNF blockers. For adults, there is an increased risk of lymphoma, leukemia, and skin cancers. A rare and often fatal type of cancer called hepatosplenic T-cell lymphoma has been observed in some patients, particularly adolescent and young adult males with inflammatory bowel disease who were also using other immunosuppressants.

Hepatitis B Reactivation

The use of TNF blockers can lead to the reactivation of the hepatitis B virus in people who are carriers. This can result in serious liver damage or death. Screening for hepatitis B is usually required before beginning treatment, and carriers should be monitored closely during and after therapy.

Heart Failure

New or worsening congestive heart failure has been reported with the use of Simponi. Patients with existing heart conditions require close monitoring for symptoms such as shortness of breath, sudden weight gain, or swelling of the feet and ankles.

Neurological Events

TNF blockers have been linked to rare cases of new or worsening demyelinating diseases, including multiple sclerosis, Guillain-Barré syndrome, and optic neuritis.

Vaccinations

People using Simponi should not receive live vaccines, as the medication may decrease the body's ability to respond safely to the vaccine. It is generally recommended that all vaccinations be brought up to date before starting treatment.

Hypersensitivity

Serious allergic reactions, including anaphylaxis, can occur. If a serious reaction happens, the medication must be discontinued immediately and medical attention sought.

Pregnancy

There is limited data on the use of Simponi in pregnant women. While animal studies have not shown direct evidence of harm to the fetus, golimumab is known to cross the placenta, especially during the third trimester. This means the medication could potentially affect the immune system of the newborn.

If Simponi is used during pregnancy, it is important to discuss the timing of infant vaccinations with a healthcare provider. Because the drug may remain in the infant's system for some time, live vaccines are generally avoided for at least six months after the mother's last dose of Simponi during pregnancy.

Breastfeeding

It is not known whether Simponi passes into human breast milk or how it might affect a nursing infant. Because many medications are excreted in human milk and there is a potential for serious adverse reactions in the baby, a decision must be made whether to discontinue nursing or discontinue the medication. Patients should consult with their healthcare provider to weigh the benefits of breastfeeding against the potential risks to the infant.

Available Forms

Simponi is supplied as a sterile solution for administration in the following delivery formats:

• Subcutaneous Injection: This form is intended for injection under the skin and is available as a single-dose prefilled syringe or a single-dose autoinjector.
• Intravenous Infusion: This form is a solution administered directly into a vein by a healthcare professional in a clinical setting.

FDA Approval History

Simponi was first approved by the U.S. Food and Drug Administration (FDA) in April 2009. It is a tumor necrosis factor (TNF) blocker developed to treat specific autoimmune and inflammatory disorders.

Approved Indications

The FDA has approved Simponi for the treatment of the following conditions in adult patients:

• Moderate to severe rheumatoid arthritis: Used in combination with methotrexate.
• Active psoriatic arthritis: May be used alone or in combination with methotrexate.
• Active ankylosing spondylitis.
• Moderate to severe ulcerative colitis: For patients who have not responded to other treatments or who require continuous steroid therapy.

Boxed Warning

Simponi carries a boxed warning, which is the FDA's most serious warning for medications. The warning covers two primary areas of concern:

• Serious Infections: Patients treated with Simponi are at increased risk for developing serious infections that may lead to hospitalization or death. These include tuberculosis (TB), bacterial sepsis, and invasive fungal infections. Healthcare providers must test patients for TB before starting treatment and monitor them closely for signs of infection during therapy.
• Malignancy: Lymphoma and other types of cancer, some fatal, have been reported in children and adolescent patients treated with TNF blockers. While Simponi is approved for use in adults, the risk of malignancy is a recognized concern for this class of drugs.

Safety and Monitoring

Regulatory guidelines require that Simponi should not be started in patients with an active, clinically important infection. If a serious infection or sepsis develops during treatment, the medication should be discontinued. Additionally, the FDA monitors reports of rare but serious side effects, including the reactivation of hepatitis B virus in chronic carriers and the development of new or worsening neurological problems such as multiple sclerosis.

The cost of Simponi is influenced by several factors, including the specific formulation prescribed and the method of administration. Because it is a prescription biologic medication, it is typically handled through specialty pharmacies rather than standard retail pharmacies.

Insurance and Coverage

Coverage for Simponi varies depending on the individual's health insurance plan. It may be covered under a pharmacy benefit or a medical benefit, depending on whether the medication is self-injected or administered by a healthcare professional in a clinical setting.

Administration Factors

• Self-Injection: Simponi is available as a subcutaneous injection that patients may be trained to administer at home.
• Clinical Administration: Simponi Aria is an intravenous infusion that must be administered by a healthcare provider, which may involve additional costs for the office visit and professional services.

Patients are encouraged to check with their insurance provider to determine their specific coverage levels, copayments, or coinsurance requirements.